Synthesis and angiotensin II receptor antagonistic activities of benzimidazole derivatives bearing acidic heterocycles as novel tetrazole bioisosteres

Journal of Medicinal Chemistry

Volumn 39, Issue 26, 1996, Pages 5228-5235

  Kohara, Yasuhisa ^a   Kubo, Keiji ^a   Imamiya, Eiko ^a   Wada, Takeo ^a   Inada, Yoshiyuki ^a   Naka, Takehiko ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; BENZIMIDAZOLE DERIVATIVE; HETEROCYCLIC COMPOUND; TAK 536; TETRAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ADRENAL CORTEX; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; INTRAVENOUS DRUG ADMINISTRATION; LIPOPHILICITY; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRESSOR RESPONSE; RAT;

BENZIMIDAZOLES; MAGNETIC RESONANCE SPECTROSCOPY; RECEPTORS, ANGIOTENSIN; SPECTROPHOTOMETRY, INFRARED;

EID: 0030480485     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm960547h     Document Type: Article

References (35)

1. Naka, T.; Inada, Y. Heterocyclic Compounds, Their Production and Use. Eur. Pat. 520423, 1993; Chem Abstr. 1993, 119, 49388x.
2. Naka, T.; Inada, Y. Heterocyclic Compounds, Their Production and Use. Eur. Pat. 520423, 1993; Chem Abstr. 1993, 119, 49388x.
3. Ferrario, C. M. The Renin-Angiotensin System: Importance in Physiology and Pathology. J. Cardiovasc. Pharmacol. 1990, 15 (Suppl. 3), S1-S5.
4. (a) Coulter, M. D.; Edwards, I. R. Cough Associated with Captopril and Enalapril. Br. Med. J. 1987, 294, 1521-1523.
5. (b) Erdös, E. G.; Skidgel, R. A. The Unusual Substrate Specificity and the Distribution of Human Angiotensin I Converting Enzyme. Hypertension 1986, 8 (Suppl. I), I-34-I-37.
6. Kubo, K.; Kohara, Y.; Imamiya, E.; Sugiura, Y.; Inada, Y.; Furukawa, Y.; Nishikawa, K.; Naka, T. Nonpeptide Angiotensin II Receptor Antagonists. Synthesis and Biological Activity of Benzimidazolecarboxylic Acids. J. Med. Chem. 1993, 36, 2182-2195.
7. Kubo, K.; Kohara, Y.; Yoshimura, Y.; Inada, Y.; Shibouta, Y.; Furukawa, Y.; Kato, T.; Nishikawa, K.; Naka, T. Nonpeptide Angiotensin II Receptor Antagonists. Synthesis and Biological Activity of Potential Prodrugs of Benzimidazole-7-carboxylic Acids. J. Med. Chem. 1993, 36, 2343-2349.
8. Cho, N.; Kubo, K.; Furuya, S.; Sugiura, Y.; Yasuma, T.; Kohara, Y.; Ojima, M.; Inada, Y.; Nishikawa, K.; Naka, T. A New Class of Diacidic Nonpeptide Angiotensin II Receptor Antagonists. Bioorg. Med. Chem. Lett. 1994, 4, 35-40.
9. Kubo, K.; Inada, Y.; Kohara, Y.; Sugiura, Y.; Ojima, M.; Itoh, K.; Furukawa, Y.; Nishikawa, K.; Naka, T. Nonpeptide Angiotensin II Receptor Antagonists. Synthesis and Biological Activity of Benzimidazoles. J. Med. Chem. 1893, 36, 1772-1784.
10. (a) Stearns, R. A.; Doss, G. A.; Miller, R. R.; Chiu, S.-H. L. Synthesis and Identification of a Novel Tetrazole Metabolite of the Angiotensin II Receptor Antagonist DuP 753. Drug Metab. Dispos. 1991, 19, 1160-1162.
11. (b) Stearns, R. A.; Miller, R. R.; Doss, G. A.; Chakravarty, P. K.; Rosegay, A.; Gatto, G. J.; Chiu, S.-H. L. The Metabolism of DuP 753, a Nonpeptide Angiotensin II Receptor Antagonist, by Rat, Monkey, and Human Liver Slices. Drug Metab. Dispos. 1992, 20, 281-287.
12. (c) Huskey, S.-E. W.; Miller, R. R.; Chiu, S.-H. L. N-Glucuronidation Reaction. I. Tetrazole N-Glucuronidation of Selected Angiotensin II Receptor Antagonists in Hepatic Microsomes from Rats, Dogs, Monkeys and Humans. Drug Metab. Dispos. 1993, 21, 792-799.
13. For the prodrug approach of diacidic AII receptor antagonists, see: (a) Middlemiss, D.; Watson, S. P.; Ross, B. C.; Dowle, M. D.; Scopes, D. I. C.; Montana, J. G.; Shah, P.; Hirst, G. C.; Panchal, T. A.; Paton, J. M. S.; Pass, M.; Hubbard, T.; Hamblett, J.; Cardwell, K. S.; Jack, T. I.; Stuart, G.; Coote, S.; Bradshow, J.; Drew, G. M.; Hilditch, A.; Clark, K. L.; Robertson, M. J.; Bayliss, M. K.; Donnelly, M.; Palmer, E.; Manchee, G. R. M. Benzofuran Based Angiotensin II Antagonists Related To GR117289: Enhancement of Potency in Vitro and Oral Activity. Bioorg. Med. Chem. Lett. 1993, 3, 589-594. (b) Carini, D. J.; Ardecky, R. J.; Ensinger, C. L.; Pruitt, J. R.; Wexler, R. R.; Wong, P. C.; Huang, S.-M.; Aungst, B. J.; Timmermans, B. M. W. M. Nonpeptide Angiotensin II Receptor Antagonists: The Discovery of DMP 581 and DMP 811. Bioorg. Med. Chem. Lett. 1994, 4, 63-68. (c) Ryono, D. E.; Lloyd, J.; Poss, M. A.; Bird, J. E.; Buote, J.; Chong, S.; Dickinson, K. E. J.; Gu, Z.; Mathers, P.; Moreland, S.; Morrison, R. A.; Petrillo, E. W.; Powell, J. R.; Schaeffer, T.; Spitzmiller, E. R.; White, R. E. Orally Active Prodrugs of Quinoline-4-carboxylic Acid Angiotensin II Receptor Antagonists. Bioorg. Med. Chem. Lett. 1994, 4, 201-206.
14. For the prodrug approach of diacidic AII receptor antagonists, see: (a) Middlemiss, D.; Watson, S. P.; Ross, B. C.; Dowle, M. D.; Scopes, D. I. C.; Montana, J. G.; Shah, P.; Hirst, G. C.; Panchal, T. A.; Paton, J. M. S.; Pass, M.; Hubbard, T.; Hamblett, J.; Cardwell, K. S.; Jack, T. I.; Stuart, G.; Coote, S.; Bradshow, J.; Drew, G. M.; Hilditch, A.; Clark, K. L.; Robertson, M. J.; Bayliss, M. K.; Donnelly, M.; Palmer, E.; Manchee, G. R. M. Benzofuran Based Angiotensin II Antagonists Related To GR117289: Enhancement of Potency in Vitro and Oral Activity. Bioorg. Med. Chem. Lett. 1993, 3, 589-594. (b) Carini, D. J.; Ardecky, R. J.; Ensinger, C. L.; Pruitt, J. R.; Wexler, R. R.; Wong, P. C.; Huang, S.-M.; Aungst, B. J.; Timmermans, B. M. W. M. Nonpeptide Angiotensin II Receptor Antagonists: The Discovery of DMP 581 and DMP 811. Bioorg. Med. Chem. Lett. 1994, 4, 63-68. (c) Ryono, D. E.; Lloyd, J.; Poss, M. A.; Bird, J. E.; Buote, J.; Chong, S.; Dickinson, K. E. J.; Gu, Z.; Mathers, P.; Moreland, S.; Morrison, R. A.; Petrillo, E. W.; Powell, J. R.; Schaeffer, T.; Spitzmiller, E. R.; White, R. E. Orally Active Prodrugs of Quinoline-4-carboxylic Acid Angiotensin II Receptor Antagonists. Bioorg. Med. Chem. Lett. 1994, 4, 201-206.
15. For the prodrug approach of diacidic AII receptor antagonists, see: (a) Middlemiss, D.; Watson, S. P.; Ross, B. C.; Dowle, M. D.; Scopes, D. I. C.; Montana, J. G.; Shah, P.; Hirst, G. C.; Panchal, T. A.; Paton, J. M. S.; Pass, M.; Hubbard, T.; Hamblett, J.; Cardwell, K. S.; Jack, T. I.; Stuart, G.; Coote, S.; Bradshow, J.; Drew, G. M.; Hilditch, A.; Clark, K. L.; Robertson, M. J.; Bayliss, M. K.; Donnelly, M.; Palmer, E.; Manchee, G. R. M. Benzofuran Based Angiotensin II Antagonists Related To GR117289: Enhancement of Potency in Vitro and Oral Activity. Bioorg. Med. Chem. Lett. 1993, 3, 589-594. (b) Carini, D. J.; Ardecky, R. J.; Ensinger, C. L.; Pruitt, J. R.; Wexler, R. R.; Wong, P. C.; Huang, S.-M.; Aungst, B. J.; Timmermans, B. M. W. M. Nonpeptide Angiotensin II Receptor Antagonists: The Discovery of DMP 581 and DMP 811. Bioorg. Med. Chem. Lett. 1994, 4, 63-68. (c) Ryono, D. E.; Lloyd, J.; Poss, M. A.; Bird, J. E.; Buote, J.; Chong, S.; Dickinson, K. E. J.; Gu, Z.; Mathers, P.; Moreland, S.; Morrison, R. A.; Petrillo, E. W.; Powell, J. R.; Schaeffer, T.; Spitzmiller, E. R.; White, R. E. Orally Active Prodrugs of Quinoline-4-carboxylic Acid Angiotensin II Receptor Antagonists. Bioorg. Med. Chem. Lett. 1994, 4, 201-206.
16. (a) Wexler, R. R.; Greenlee, W. J.; Irvin, J. D.; Goldberg, M. R.; Prendergast, K.; Smith, R. D.; Timmermans, P. B. M. W. M. Nonpeptide Angiotensin II Receptor Antagonists: The Next Generation in Antihypertensive Therapy. J. Med. Chem. 1996, 39, 625-656 and references cited therein.
17. (b) Walsh, T. F.; Fitch, K. J.; MacCoss, M.; Chang, R. S. L.; Kivlighn, S. D.; Lotti, V. J.; Siegl, P. K. S.; Patchett, A. A.; Greenlee, W. J. Synthesis of New Imidazo[1,2-b]pyridine Isosteres of Potent Imidazo[4,5-b]pyridazine Angiotensin II Antagonists. Bioorg. Med. Chem. Lett. 1994, 4, 219-222.
18. (c) Quan, M. L.; DeLucca, I.; Boswell, G. A.; Chiu, A. T.; Wong, P. C.; Wexler, R. R.; Timmermans, P. B. M. W. M. Imidazolinones As Nonpeptide Angiotensin II Receptor Antagonists. Bioorg. Med. Chem. Lett. 1994, 4, 1527-1530.
19. 2 Subtypes. Bioorg. Med. Chem. Lett. 1994, 4, 2787-2792.
20. 2 Angiotensin II Antagonists I. New Orally Active 5-Carboxyl Imidazolyl Biphenyl Sulfonylureas. Bioorg. Med. Chem. Lett. 1998, 5, 2605-2610.
21. 2 Angiotensin II Antagonists II. Potent 5-α-Hydroxy acid Imidazolyl Biphenyl Sulfonylureas. Bioorg. Med. Chem. Lett. 1995, 5, 2611-2616.
22. (g) Deprez, P.; Guillaume, J.; Corbier, A.; Vevert, J.-P.; Fortin, M.; Heckmann, B. Potent 5-β-Keto Sulfoxide Imidazolyl Biphenyl Sulfonylureas. Bioorg. Med. Chem. Lett. 1995, 5, 2617-2622.
23. 2 Subtypes. J. Med. Chem. 1994, 37, 4464-4478.
24. (i) Deprez, P.; Guillaume, J.; Becker, R.; Corbier, A.; Didierlaurent, S.; Fortin, M.; Frechet, D.; Hamom, G.; Heckmann, B.; Heitsch, H.; Kleemann, H.-W.; Vevert, J.-P.; Vincent, J.-C.; Wagner, A.; Zhang, J. Sulfonylureas and Sulfonylcarbamates as New Non-Tetrazole Angiotensin II Receptor Antagonists. Discovery of a Highly Potent Orally Active (Imidazolylbiphenyl)sulfonylureas (HR 720), J. Med. Chem. 1995, 38, 2357-2377.
25. For heterocycles as the tetrazole bioisostere, see: (a) Soll, R. M.; Kinney, W. A.; Primeau, J.; Garrick, L.; McCaully, R. J.; Colatsky, T.; Oshiro, G.; Park, C. H.; Hartupee, D.; White, V.; McCallum, J.; Russo, A.; Dinish, J.; Wojdan, A. 3-Hydroxy-3-Cyclobutene-1,2-Dione: Application of a Novel Carboxylic Acid Bioisostere to an In-vivo Active Non-tetrazole Angiotensin II Antagonist. Bioorg. Med. Chem. Lett. 1993, 3, 757-760. (b) Kim, D.; Mantlo, N. B.; Chang, R. S. L.; Kivlighn, S. D.; Greenlee, W. J. Evaluation of Heterocyclic Acid Equivalents as Tetrazole Replacements in Imidazopyridine-Based Nonpeptide Angiotensin II Receptor Antagonists. Bioorg. Med. Chem. Lett. 1994, 4, 41-44. (c) Ferrari, B.; Taillades, J.; Perreaut, P.; Bernhart, C.; Gougat, J.; Guiraudou, P.; Cazaubon, C.; Roccon, A.; Nisato, D.; Le Fur, G.; Brelière, J. C. Development of Tetrazole Bioisosteres in Angiotensin II Antagonists. Bioorg. Med. Chem. Lett. 1994, 4, 45-50.
26. For heterocycles as the tetrazole bioisostere, see: (a) Soll, R. M.; Kinney, W. A.; Primeau, J.; Garrick, L.; McCaully, R. J.; Colatsky, T.; Oshiro, G.; Park, C. H.; Hartupee, D.; White, V.; McCallum, J.; Russo, A.; Dinish, J.; Wojdan, A. 3-Hydroxy-3-Cyclobutene-1,2-Dione: Application of a Novel Carboxylic Acid Bioisostere to an In-vivo Active Non-tetrazole Angiotensin II Antagonist. Bioorg. Med. Chem. Lett. 1993, 3, 757-760. (b) Kim, D.; Mantlo, N. B.; Chang, R. S. L.; Kivlighn, S. D.; Greenlee, W. J. Evaluation of Heterocyclic Acid Equivalents as Tetrazole Replacements in Imidazopyridine-Based Nonpeptide Angiotensin II Receptor Antagonists. Bioorg. Med. Chem. Lett. 1994, 4, 41-44. (c) Ferrari, B.; Taillades, J.; Perreaut, P.; Bernhart, C.; Gougat, J.; Guiraudou, P.; Cazaubon, C.; Roccon, A.; Nisato, D.; Le Fur, G.; Brelière, J. C. Development of Tetrazole Bioisosteres in Angiotensin II Antagonists. Bioorg. Med. Chem. Lett. 1994, 4, 45-50.
27. For heterocycles as the tetrazole bioisostere, see: (a) Soll, R. M.; Kinney, W. A.; Primeau, J.; Garrick, L.; McCaully, R. J.; Colatsky, T.; Oshiro, G.; Park, C. H.; Hartupee, D.; White, V.; McCallum, J.; Russo, A.; Dinish, J.; Wojdan, A. 3-Hydroxy-3-Cyclobutene-1,2-Dione: Application of a Novel Carboxylic Acid Bioisostere to an In-vivo Active Non-tetrazole Angiotensin II Antagonist. Bioorg. Med. Chem. Lett. 1993, 3, 757-760. (b) Kim, D.; Mantlo, N. B.; Chang, R. S. L.; Kivlighn, S. D.; Greenlee, W. J. Evaluation of Heterocyclic Acid Equivalents as Tetrazole Replacements in Imidazopyridine-Based Nonpeptide Angiotensin II Receptor Antagonists. Bioorg. Med. Chem. Lett. 1994, 4, 41-44. (c) Ferrari, B.; Taillades, J.; Perreaut, P.; Bernhart, C.; Gougat, J.; Guiraudou, P.; Cazaubon, C.; Roccon, A.; Nisato, D.; Le Fur, G.; Brelière, J. C. Development of Tetrazole Bioisosteres in Angiotensin II Antagonists. Bioorg. Med. Chem. Lett. 1994, 4, 45-50.
28. Lipinski, C. A. Bioisosterism in Drug Design. Annu. Rep. Med. Chem. 1986, 21, 283-291.
29. Kohara, Y.; Imamiya, E.; Kubo, K.; Wada, T.; Inada, Y.; Naka, T. A New Class of Angiotensin II Receptor Antagonists with a Novel Acidic Bioisostere. Bioorg. Med. Chem. Lett. 1995, 5, 1903-1908.
30. The detailed study on the synthesis and assignment of the 5-oxo-1,2,4-thiadiazole and 5-thioxo-1,2,4-oxadiazole derivatives will be reported elsewhere.
31. Birr, E. J. Ger. 950537, 1956; Chem. Abstr. 1956, 53, 17737e.
32. Alessi, T. R.; Dolak, T. M.; Ellingboe, J. W. Novel Naphthalenylalkyl-3H-1,2,3,5-oxathiadiazole-2-oxides Useful as Antihyperglycemic Agents. U.S. Pat. 4,897,405, 1990.
33. -7 M) (Bioorg. Med. Chem. Lett. 1992, 2, 1775-1779).
34. Thornber, C. W. Isosterism and Molecular Modification in Drug Design. Chem. Rev. 1979, 8, 563-580.
35. 2O (2:3) at 26°C by potentiometric titration with standardized 0.1 N NaOH.